Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. DFTX
10. NKE

Go back to Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus

Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results

February 6, 2020 4:05 PM EST

-- First Quarter Fiscal 2020 Revenues of $17.2M; Increase of 49% over First Quarter Fiscal 2019

-- Reaches Settlement Agreement with Agilent in Litigation --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2020, ended December 31, 2019. In a separate press release issued today, the company announced a settlement agreement with Agilent Technologies in the litigation originally filed... More